Axiom MRC has updated all it's market research reports with the Economic Impact Analysis of COVID19 Pandemic on the market. Our team of analyst are following Comprehensive Three Dimensional (3D) Research Methodology along with large number primary interviews with key industry participants to bring insightful market reports to meet the current market requirements.
Hypertension has a considerable worldwide burden and is a major risk factor for cardiovascular disease. Despite the use of lifestyle measures and medical therapy, a large proportion of patients remain treatment ‘resistant’ and fail to have adequate control of blood pressure. This may adversely affect both future cardiovascular events and mortality. Moreover, renal denervation is one of several innovative device-based interventional therapies, which is aiming for better blood pressure control. It is safe, minimally invasive and does not leave any implants behind. This has been shown previously to be important in both resistant hypertension and in other disease states including heart failure.
Furthermore, high blood pressure is more common in some areas of the United States than in others. According to centers for disease control and prevention (CDC), in 2016, about 75 million American adults that is 29% have high blood pressure. Likewise, in 2015, the occurrence of hypertension was about 33.2% in adults aged 20 and over. In addition, according to public health England, high blood pressure affects more than 1 in 4 adults in England, around 12.5 million people in 2015. The prevalence of high blood pressure for adults in England in 2015 was 31% among men and 26% among women, with little change over the last few years. Owing to this great prevalence of high blood pressure in various regions of the world, the market of renal denervation is anticipated to grow significantly in near future.
The global renal denervation market is driven by key factors such as increasing prevalence and incidence of hypertension and blood pressure, improvement of healthcare infrastructure in developing countries and regulatory approvals. However, factors such as strict approval process for renal denervation devices and patient discomfort & pain that arises during the procedure are hampering the renal denervation market globally. Whereas, factors such as advancement in technology in developing countries are some opportunities for this market.
The renal denervation market is segmented by technology, product and geography.
Based on technology, the renal denervation market is classified into ultrasound ablation, radiofrequency ablation, pharmacologic ablation and microinfusion. Ablation procedures are gaining rapid popularity across the globe on account of the fact that they are used in minimally invasive ablation procedures. The ultrasound ablation segment is growing significantly due to its non-invasive nature, not requiring even a laparoscopic procedure. Furthermore, radio frequency ablation which is a minimally invasive procedure and provides an expeditious relief from pain associated with chronic diseases. The procedure has several benefits such as low risk of side effects, short recovery period, and reduced post-procedure complications, among others.
Various products were studied in this report which includes catheters, RF generator and nerve modifying agents. Catheterization is a primary co-procedure performed with varied other medical procedures such as angioplasty, cardiac electrophysiology and neurosurgery, wherein catheters are used. The catheters segment is driven by increase in prevalence of cardiovascular diseases and growth in demand for minimal invasive surgeries.
The renal denervation market report is studied across the key countries of North America, Europe, Asia Pacific and Rest of the World. Europe dominated the renal denervation market in 2018, due to high number of drug-resistant hypertension cases and initiatives, such as R&D, for the development of effective devices. However, Asia-Pacific is expected estimated to witness the highest growth over the forecast period, due to increasing target population coupled with rising prevalence of diabetes.
The key players operating in the renal denervation market includes Medtronic Inc, Boston Scientific Corporation., St. Jude Medical, Recor Medical, Inc., Cordis Corporation, Terumo Corporation, Mercator Medsystems, Inc, Kona Medical, Inc, Cardiosonic Ltd, Covidien PLC., Ablative Solutions, Inc., Renal Dynamics Limited., Bioscience Webster Inc. and Hansen Medical. Leading companies have invested massive capital in research & development and mergers & acquisitions activities to develop innovative products in the market.
The renal denervation market is segmented by technology, product and geography. Based on technology, the renal denervation market is classified into ultrasound ablation, radiofrequency ablation, pharmacologic ablation and microinfusion. Ablation procedures are gaining rapid popularity across the globe on account of the fact that they are used in minimally invasive ablation procedures. The ultrasound ablation segment is growing significantly due to its non-invasive nature, not requiring even a laparoscopic procedure. Furthermore, radio frequency ablation which is a minimally invasive procedure and provides an expeditious relief from pain associated with chronic diseases. The procedure has several benefits such as low risk of side effects, short recovery period, and reduced post-procedure complications, among others.
Various products were studied in this report which includes catheters, RF generator and nerve modifying agents. Catheterization is a primary co-procedure performed with varied other medical procedures such as angioplasty, cardiac electrophysiology and neurosurgery, wherein catheters are used. The catheters segment is driven by increase in prevalence of cardiovascular diseases and growth in demand for minimal invasive surgeries.
The renal denervation market report is studied across the key countries of North America, Europe, Asia Pacific and Rest of the World. Europe dominated the renal denervation market in 2018, due to high number of drug-resistant hypertension cases and initiatives, such as R&D, for the development of effective devices. However, Asia-Pacific is expected estimated to witness the highest growth over the forecast period, due to increasing target population coupled with rising prevalence of diabetes.
Why to buy this report:
